Inhaled technosphere insulin in children with diabetes: the INHALE-1 extension study
Beck RW, Kanapka L, Monzavi R, et al.
Diabetes Technol Ther. Pub. online 4 Feb 2026.
Leggi
Breaking news
Effect of diabetes self-management education in type 2 diabetes management – a systematic umbrella review of meta-analysis
Ma L, Zhao WS, Wang R, et al.
BMC Endocr Disord. Pub. online 5 Feb 2026.
Leggi
FDA. Glucose Monitor Sensor Recall: Abott Diabetes Care Removes Certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors
4 febbraio 2026
Leggi
Impact of screening programmes for type 1 diabetes in youth: a systematic review and meta-analysis
Franceschi R, Mozzillo E, Marigliano M, et al.
Diabet Med. Pub. online 31 Jan 2026.
Leggi
Oral semaglutide and heart failure outcomes in persons with type 2 diabetes: a secondary analysis of the SOUL randomized clinical trial
Pop-Busui R, Rasmussen S, Deanfield JE, et al.
JAMA Intern Med. Pub. online 2 Feb 2026.
Leggi
Ocular light and optical radiation exposure as a modifiable environmental determinant of health: expert consensus on research gaps and priorities
Spitschan M, Biller AM, Broszio K, et al.
BMC Med. Pub. online 29 Jan 2026.
Leggi
EMA. Semaglutide (Kayshild): The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Kayshild (semaglutide), intended for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH).
29 gennaio 2026
Leggi
AGENAS. Pubblicato il Glossario nazionale di Telemedicina
30 gennaio 2026
Leggi
FDA. MOUNJARO (TIRZEPATIDE): Never share MOUNJARO KwikPen between patients, even if the pen needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
20 gennaio 2026
Leggi
AIFA. PREPARAZIONI GALENICHE A SCOPO DIMAGRANTE – DIVIETI DI PRESCRIZIONE. Divieto ai medici di prescrivere e ai farmacisti di eseguire preparazioni galeniche a scopo dimagrante contenenti il principio attivo paroxetina e altri principi attivi appartenenti alla classe degli inibitori selettivi della ricaptazione della serotonina (SSRI).
17 gennaio 2026
Leggi